Match!
Jiajia Zhang
Johns Hopkins University
22Publications
4H-index
257Citations
Publications 22
Newest
PURPOSEThe risk of immune checkpoint inhibitor therapy–related GI adverse events in patients with cancer and inflammatory bowel disease (IBD) has not been well described. We characterized GI advers...
Source
Purpose: Neoadjuvant PD-1 blockade is a promising treatment for resectable non-small cell lung cancer (NSCLC), yet immunological mechanisms contributing to tumor regression and biomarkers of response are unknown. Using paired tumor/blood samples from a phase 2 clinical trial (NCT02259621), we explored whether the peripheral T cell clonotypic dynamics can serve as a biomarker for response to neoadjuvant PD-1 blockade. Experimental Design: T cell receptor (TCR) sequencing was performed on serial p...
Source
Source
#1Jiajia Zhang (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 4
#2Charles Haines (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 1
Last.Cynthia L. Sears (JHUSOM: Johns Hopkins University School of Medicine)H-Index: 35
view all 9 authors...
Background Microbiome dysbiosis predisposes to colorectal cancer (CRC), but a population-based study of oral antibiotic exposure and risk patterns is lacking. Objective To assess the association between oral antibiotic use and CRC risk. Design A matched case–control study (incident CRC cases and up to five matched controls) was performed using the Clinical Practice Research Datalink from 1989 to 2012. Results 28 980 CRC cases and 137 077 controls were identified. Oral antibiotic use was associat...
1 CitationsSource
#1Jiajia Zhang (Johns Hopkins University)H-Index: 4
#2Charles F. Haines (Johns Hopkins University)H-Index: 3
Last.Cynthia L. Sears (Johns Hopkins University)H-Index: 30
view all 9 authors...
Source
#1Hamzah Abu-Sbeih (University of Texas MD Anderson Cancer Center)H-Index: 6
#2Faisal S. Ali (St. Joseph Hospital)H-Index: 4
Last.Yinghong Wang (University of Texas MD Anderson Cancer Center)H-Index: 9
view all 19 authors...
PURPOSEImmune checkpoint inhibitor (ICI) therapy often is suspended because of immune-mediated diarrhea and colitis (IMDC). We examined the rate of and risk factors for IMDC recurrence after ICI re...
Source
Source
#1Jiajia Zhang (Johns Hopkins University)H-Index: 4
#2Zhicheng Ji (Johns Hopkins University)
Last.Kellie N. Smith (Johns Hopkins University)H-Index: 8
view all 3 authors...
Abstract Anti-tumor T cells are the soldiers in the body's war against cancer. Effector T cells can detect and eliminate cells expressing their cognate antigen via activation through engagement of the T cell receptor (TCR) with its cognate peptide:MHC complex. Owing to the recent success of immunotherapy in the treatment of many different cancer types, research efforts have shifted toward identifying and tracking anti-tumor T cell responses upon treatment in cancer patients. While traditional me...
Source
#1Nicolas J. Llosa (Johns Hopkins University)H-Index: 8
#2Brandon Luber (Johns Hopkins University)H-Index: 20
Last.Franck Housseau (Johns Hopkins University)H-Index: 26
view all 24 authors...
Purpose: Approximately 10% of patients with mismatch repair–proficient (MMRp) colorectal cancer showed clinical benefit to anti-PD-1 monotherapy (NCT01876511). We sought to identify biomarkers that delineate patients with immunoreactive colorectal cancer and to explore new combinatorial immunotherapy strategies that can impact MMRp colorectal cancer. Experimental Design: We compared the expression of 44 selected immune-related genes in the primary colon tumor of 19 patients with metastatic color...
2 CitationsSource
#1Aanika Balaji (Johns Hopkins University)
#2Jiajia Zhang (Johns Hopkins University)H-Index: 4
Last.Jarushka Naidoo (Johns Hopkins University)H-Index: 19
view all 19 authors...
PURPOSE:Immune checkpoint inhibitors (ICIs) cause immune-related adverse events (irAEs). The proportion of patients who are hospitalized for irAEs and their spectrum, management, and outcomes are n...
Source
123